SCHEMBL6182662

SCHEMBL6182662

C[C@@H]1COC[C@@H](C)N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL633324 1.00
SCHEMBL15508385 1.00
SCHEMBL3497544 1.00
SCHEMBL31352548 1.00
SCHEMBL491883 1.00
SCHEMBL4204733 1.00
SCHEMBL92625 1.00
Hydrochloric Acid SCHEMBL6132910 0.97
Hydrochloric Acid SCHEMBL15519440 0.97
Hydrochloric Acid SCHEMBL71659 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296930-A1 BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2025-09-25 US disclosed
US-20250214998-A1 CYCLIC COMPOUNDS AS RECEPTOR MODULATING THERAPEUTICS AND METHODS AND USES THEREOF BIONOMICS LTD (AU) 2025-07-03 US disclosed
US-12331026-B2 Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors NIKANG THERAPEUTICS, INC. (US) 2025-06-17 US disclosed
CN-115368356-B Bicyclic heterocyclic compounds and therapeutic uses thereof 阿斯特克斯治疗有限公司 2025-05-09 CN disclosed
US-12275732-B2 Cyclic compounds as receptor modulating therapeutics and methods and uses thereof BIONOMICS LIMITED (AU) 2025-04-15 US disclosed
WO-2025072462-A1 SULFONAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed
WO-2025072539-A1 AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed
WO-2025067111-A1 MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION 苏州必扬医药科技有限公司 2025-04-03 WO disclosed
US-20250066313-A1 Methods of Synthesis of Chiral 3,5-Disubstituted Morpholine Compounds and Intermediates Useful Therein BEONE MEDICINES I GMBH (CH) 2025-02-27 US disclosed
EP-4499634-A1 SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS Nikang Therapeutics, Inc. (US) 2025-02-05 EP disclosed
US-20150148328-A1 Novel 2,3-Dihydro-1H-imidazopyrimidin-5-one and this 1,2,3,4-tetrahydropyrimidopyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof SANOFI (FR) 2015-05-28 US disclosed
US-20150148328-A1 Novel 2,3-Dihydro-1H-imidazopyrimidin-5-one and this 1,2,3,4-tetrahydropyrimidopyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof SANOFI (FR) 2015-05-28 US disclosed
US-8912220-B2 Compounds and methods of use thereof Galenea Pharmaceuticals 2014-12-16 US disclosed
US-8912220-B2 Compounds and methods of use thereof Galenea Pharmaceuticals 2014-12-16 US disclosed
WO-2014060770-A1 BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2014-04-24 WO disclosed
US-20110144090-A1 COMPOUNDS AND METHODS OF USE THEREOF GALENEA CORPORATION 2011-06-16 US disclosed
US-20110144090-A1 COMPOUNDS AND METHODS OF USE THEREOF GALENEA CORPORATION 2011-06-16 US disclosed
US-6979741-B2 Acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2005-12-27 US disclosed
EP-1478437-B1 ACC INHIBITORS PFIZER PROD INC (US) 2005-08-31 EP disclosed
US-20030187254-A1 Acetyl-CoA carboxylase inhibitors PFIZER INC. 2003-10-02 US disclosed